Clinical Trial Detail

NCT ID NCT02352948
Title A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ARCTIC)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Vinorelbine

Durvalumab + Tremelimumab

Gemcitabine

Erlotinib

Tremelimumab

Age Groups: senior adult

Additional content available in CKB BOOST